Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2018-05-17 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于参股孙公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the completion of business registration and obtaining a business license for a subsidiary company. It details the establishment of a new subsidiary, its board structure, and operational risks. There is no financial data, no mention of a report being attached or published, and no regulatory certification. The content is about corporate structural changes and operational updates related to a subsidiary, which fits best under general regulatory announcements. It does not fit into categories like Annual Report, Interim Report, or Capital/Financing Update. Given the nature and length of the document, the best classification is Regulatory Filings (RNS).
2018-05-17 Chinese
关于控股孙公司完成工商注册登记并取得营业执照的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the completion of business registration and obtaining a business license for a controlled subsidiary. It details the establishment of a wholly-owned subsidiary by a controlled sub-subsidiary, including registration details and business scope. There is no financial data, no mention of financial results, no regulatory certifications, or voting results. The document is a corporate announcement about a subsidiary's registration and business license acquisition, which fits best under general regulatory announcements. It does not fit into categories like Annual Report, Interim Report, Capital Update, or Management Information. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length is short and it is an announcement, not a report itself.
2018-05-04 Chinese
使用闲置募集资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the progress of cash management using idle raised funds. It details the purchase and redemption of financial products such as bank wealth management products and structured deposits, including amounts, dates, and yields. The document is relatively short (2307 characters) and focuses on updates about the company's use of idle raised funds for cash management, which is a financing activity. There is no indication that this is a full financial report, audit, or earnings release. It is not a report publication announcement since it contains substantive content rather than just a notice of report availability. The content fits best under Capital/Financing Update (CAP) as it relates to the company's financing activities and management of raised capital.
2018-05-02 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the progress of cash management using idle funds. It details the company's purchase and management of various financial products such as open-ended wealth management products, fixed income products, and structured deposits. The document includes specific dates, amounts, and counterparties involved in these financial transactions. It is not a full financial report, earnings release, or management discussion, but rather an update on the company's capital management activities. The document length is about 2077 characters, which is relatively short and focused on financing activities. Therefore, it fits best under the category of Capital/Financing Update (CAP).
2018-05-02 Chinese
关于全资子公司取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding its wholly-owned subsidiary obtaining a medical device registration certificate. It details the product registration, market situation, and potential impact on the company. There is no financial data, no mention of a report or filing type such as annual or quarterly report, earnings release, or regulatory certification. The document is an official announcement about a regulatory approval related to product registration, not a financial or governance report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2018-05-02 Chinese
2017年年度权益分派实施公告
Notice of Dividend Amount Classification · 100% confidence The document is titled as an announcement regarding the implementation of the 2017 annual equity distribution (dividend) by the company. It details the dividend per share, relevant dates for dividend distribution, tax treatment, and the method of distribution. It references the approval of the dividend plan at the 2018 shareholders' meeting. The document is an announcement of dividend amount and payment details rather than a full financial report or other types of filings. The length is about 2200 characters, which is short and typical for a dividend announcement. Therefore, the document fits the category of Notice of Dividend Amount (DIV).
2018-04-26 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.